Neoadjuvant Chemoimmunotherapy Shows Superiority in Non

The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 levels less than 1%.

Related Keywords

, Non Small Cell Lung Cancer , Nsclc , Oncology ,